(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -3.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Macrogenics's revenue in 2026 is $149,500,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2026 to be $4,919,094,672, with the lowest MGNX revenue forecast at $685,131,923, and the highest MGNX revenue forecast at $8,862,225,911. On average, 7 Wall Street analysts forecast MGNX's revenue for 2027 to be $5,075,950,478, with the lowest MGNX revenue forecast at $3,737,083,216, and the highest MGNX revenue forecast at $6,566,589,079.
In 2028, MGNX is forecast to generate $9,621,082,605 in revenue, with the lowest revenue forecast at $3,737,083,216 and the highest revenue forecast at $14,561,277,815.